Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daito Pharmaceutical Co's quarterly market cap
increased
from Aug. 2025 (円36,302 Mil) to Nov. 2025 (円38,686 Mil) and
increased
from Nov. 2025 (円38,686 Mil) to Feb. 2026 (円42,871 Mil).
Daito Pharmaceutical Co's annual market cap
declined
from May. 2024 (円34,042 Mil) to May. 2025 (円29,536 Mil) but then
increased
from May. 2025 (円29,536 Mil) to May. 2026 (円34,550 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Daito Pharmaceutical Co's Enterprise Value for Today is 円46,012 Mil.
Daito Pharmaceutical Co (TSE:4577) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Daito Pharmaceutical Co Market Cap Related Terms
Daito Pharmaceutical Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Daito Pharmaceutical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daito Pharmaceutical Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daito Pharmaceutical Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Daito Pharmaceutical Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Daito Pharmaceutical Co's Market Cap for the fiscal year that ended in May. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daito Pharmaceutical Co (TSE:4577) has a Market Cap of 円37,626 Mil as of Jul. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Daito Pharmaceutical Co and its competitors. According to the industry distribution chart, Daito Pharmaceutical Co ranks #509 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 49.7%.
Is Daito Pharmaceutical Co's Market Cap too high?
Daito Pharmaceutical Co's current Market Cap is 円37,626 Mil. Based on the distribution chart, Daito Pharmaceutical Co ranks #509 out of 1024 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Daito Pharmaceutical Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Daito Pharmaceutical Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Daito Pharmaceutical Co ranks #509 out of 1024 companies for Market Cap. This puts Daito Pharmaceutical Co in the upper half of its industry. The industry median Market Cap is 225.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 225.62, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Daito Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 225.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daito Pharmaceutical Co's current Market Cap is 円37,626 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daito Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Daito Pharmaceutical Co (TSE:4577) is currently considered Fairly Valued. The stock's GF Value™ is 円1,278.05, compared to a current price of 円1,309.00 — trading 2.4% above its estimated fair value. The current Market Cap is 円37,626 Mil. Daito Pharmaceutical Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Daito Pharmaceutical Co (TSE:4577), the current Market Cap is 円37,626 Mil as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daito Pharmaceutical Co (TSE:4577) Overvalued in 2026?
Based on GuruFocus' analysis, Daito Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円1,309.00 is trading 2.4% above its estimated GF Value™ of 円1,278.05.
GuruFocus considers Daito Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4577:
Market Cap: 円37,626 Mil
GF Value™: 円1,278.05 vs. price of 円1,309.00 (2.4% above fair value)
No single metric tells the full story. See the TSE:4577 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4577 has been successfully added to your 
